Primary Analysis results from M72/AS01E vaccine trial
In a a multicenter, double-blind, randomised, placebo-controlled trial conducted in three African countries in which tuberculosis is endemic (Kenya, South Africa, and Zambia), the M72/AS01E TB vaccine provided 54.0% protection for M. tuberculosis–...
Social Reponsiveness
Established in 2001, the South African Tuberculosis Vaccine Initiative (SATVI) was presented with the University of Cape Town’s (UCT) 2018 Social Responsiveness Award at the Faculty of Health Sciences graduation ceremony on Saturday, 13 April 2019
2018 Tb under the Spotlight Science Engagement
The “TB Under the Spotlight Science Engagement” programme was conceptualised and presented by South African Tuberculosis Vaccine Initiative (SATVI) with scientists from the Division of Molecular Biology and Human Genetics at Stellenbosch University...
Biomarker discovery offers hope for new TB vaccine development
A team of scientists from the University of Cape Town, Oxford University and the London School of Hygiene & Tropical Medicine have made a discovery that reveals how we can improve development of more effective vaccines against tuberculosis.
Community Engagement
Carina's Choice: SATVI collaborated with UCT Drama Department and Worcester Secondary School in developing this play which was performed by learners from Worcester Secondary School at 8 local high schools reaching approximately 8 000 adolescents in...


Tuesday, 22 October 2019
September 2019 Latest research: Plasma Type I IFN Protein Concentrations in Human Tuberculosis

SATVI researchers Professors Mark Hatherill, Tom Scriba, Dr Bilek, Darboe, Mbandi, Penn-Nicholson have co-authored a research article titled "Plasma Type I IFN Protein Concentrations in Human Tuberculosis." appearing in the Frontiers in Cellular and Infection Microbiology.

Publication Date:
Fri, 13 Sep 2019 - 23:00
September 2019 Latest Research Non-invasive biomarker for assessing adequacy of treatment and predicting relapse in patients treated for pulmonary tuberculosis.

Professor Mark Hatherill has co-authored a journal article titled "FDG-PET/CT as a non-invasive biomarker for assessing adequacy of treatment and predicting relapse in patients treated for pulmonary tuberculosis" appearing in the Journal of Nuclear Medicine.

Publication Date:
Fri, 13 Sep 2019 - 22:45
27 August 2019 Vacancy: Postdoctoral Fellowship TB Immunology NOW CLOSED

We are inviting applications for a postdoctoral fellowship in human immunology to conduct research aimed at identifying lung immune signatures of resistance to natural M.tb infection in a multi-cohort study. NOW CLOSED.

Publication Date:
Tue, 27 Aug 2019 - 13:15
August 2019 Latest Research Published Results MTBVAC vaccine candidate offer hope for control of tuberculosis in infants

SATVI researchers have just published an article titled: "Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial" appearing in the Lancet Respiratory Medicine journal. 

Publication Date:
Tue, 13 Aug 2019 - 09:30